References
[1] Benjamin EJ,Muntner P,Alonso A,Bittencourt MS,Callaway CW,et al.Heart disease and stroke statistics-2019 update: a report from the American Heart Association[J].Circulation,2019;139:e56-e528.
[2] Zhang S.Atrial fibrillation in mainland China:epidemiology and current management[J].Heart,2009,95(13):1052-1055.
[3] Chugh SS,Havmoeller R,Narayanan K,Singh D,Rienstra M,et al.Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study[J].Circulation,2014;129:837-847.
[4] Colilla S,Crow A,Petkun W,Singer DE,Simon T,Liu X.Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population[J].Am J Cardiol,2013;112:1142-1147.
[5] Krijthe BP,Kunst A,Benjamin EJ,Lip GY,Franco OH,Hofman A,Witteman JC,Stricker B-H,Heeringa J.Projections on the number of individuals with atrial fibrillation in the Europ-ean Union, from 2000 to 2060[J].Eur Heart J,2013;34:2746-2751.
[6] Staerk L,Sherer JA,Ko D,Benjamin EJ,Helm RH.Atrial fibrillation: epidemiology,pathop-hysiology, and clinical outcomes[J].Circ Res,2017;120:1501-1517.
[7] Chen C, Zhou X, Zhu M, Chen S, Chen J, Cai H, Dai J, Xu X, Mao W. Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta analysis of evidence from randomized controlled trials[J]. J Interv Card El-ectrophysiol 2018;52:9-18.
[8] Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation:the CABANA randomized clinical trial[J]. JAMA 2019;321:1261-1274.
[9] Noseworthy PA, Gersh BJ, Kent DM, Piccini JP, Packer DL, Shah ND, Yao X.Atrial fibrillation ablation in practice: assessing CABANA generalizability[J]. Eur Heart J 2019;40:1257-1264.
[10] Blomström-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L, Kennebä-ck G, Rubulis A, Malmborg H, Raatikainen P, Lönnerholm S, Höglund N, Mörtsell D. E-ffect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial[J].JAMA 2019;321:1059-1068.
[11] January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American C-ollege of Cardiology/American Heart Association Task Force on Clinical Practice Guidelin-es and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons[J]. Circulation,2019;140(2):e125-e151.
[12] Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)[J].Eur Heart J,2021;42(5):373-498.
[13] Mujović N, Marinković M, Lenarczyk R, Tilz R, Potpara TS. Catheter Ablation of Atrial Fibrillation: An Overview for Clinicians[J]. Advances in Therapy, 2017, 34(62):1897-1917.
[14] Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, et al. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation[J]. N Engl J Med,2021,384(4):305-315.
[15] Kawaji T, Shizuta S, Aizawa T, Yamagami S, Kato M, Yokomatsu T, Miki S, Ono K, Kimura T. Impact of catheter ablation for atrial fibrillation on cardiac disorders in patients with coexisting heart failure[J]. ESC Heart Fail,2021,8(1):670-679.
[16] Xu G, Cai J, Liu Z, Liu E, Jing X, Liu T, Zhang Q, Ye L, Li G. Clinical efficacy of ”ICE-FIRE” ablation for non-paroxysmal atrial fibrillation[J]. J Interv Card Electrophys-iol,2021,60(2):205-211.
[17] Sun Y, Xie Y, Du L, Sun J, Liu Z.Inhibition of BRD4 Attenuates Cardiomyocyte Apoptosis via NF-κB pathway in a Rat Model of Myocardial Infarction[J].Cardiovascular Therapeutics, 2018:36(2).
[18] Wang Q, Sun Y, Li T, Liu L, Zhao Y, Li L, Zhang L, Meng Y. Function of BRD4 in the pathogenesis of high glucose‑induced cardiac hypertrophy[J]. Mol Med Rep. 2019;19(1):499-507.
[19] Song S, Liu L, Yu Y, Zhang R, Li Y, Cao W, Xiao Y, Fang G, Li Z, Wang X, Wang Q, Zhao X, Chen L, Wang Y, Wang Q. Inhibition of BRD4 attenuates transverse aortic constriction and TGF-β-induced endothelial-mesenchymal transition and cardiac fibrosis[J]. J Mol Cell Cardiol. 2019;127:83‐96.
[20] Shuai Song, Wei Cao, Guojian Fang, et al. Brd4 As A Novel Therapeutic Target For Atrial Fibrosis And Atrial Fibrillation[R]. Heart Rhythm Society Annual Sci-entific Sessions; May 8-11, 2019; San Francisco.
[21] Yang YM, Shi RH, Xu CX, Li L. BRD4 expression in patients with essential hypertension and its effect on blood pressure in spontaneously hypertensive rats. J Am Soc Hypertens. 2018 Dec;12(12):e107-e117.
[22] Cheng C, Liu H, Tan C, Tong D, Zhao Y, Liu X, Si W, Wang L, Liang L, Li J, et al.(2019) Mutation in NPPA causes atrial fibrillation by activating inflammation and cardiac fibrosis in a knock-in rat model. FASEB J 33:8878–8891.
[23] Wu Q, Liu H, Liao J, Zhao N, Tse G, Han B, Chen L, Huang Z, Du Y. Colchicine prevents atrial fibrillation promotion by inhibiting IL-1β-induced IL-6 release and atrial fibrosis in the rat sterile pericarditis model. Biomed Pharmacother. 2020 Sep;129:110384. doi: 10.1016/j.biopha.2020.110384.
[24] Zhang T, Wu Y, Hu Z, Xing W, Kun LV, Wang D, Hu N. Small-Molecule Integrated Stress Response Inhibitor Reduces Susceptibility to Postinfarct Atrial Fibrillation in Rats via the Inhibition of Integrated Stress Responses. J Pharmacol Exp Ther. 2021 Sep;378(3):197-206. doi: 10.1124/jpet.121.000491.
[25] Platonov PG, Mitrofanova LB, Orshanskaya V, Ho SY.Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age[J]. J Am Coll Cardiol. 2011;58(21):2225‐2232.
[26] Floria M, Radu S, Gosav EM, Cozma D, Mitu O, Ouatu A, Tanase DM, Scripcariu V, Serban LI. Left Atrial Structural Remodelling in Non-Valvular Atrial Fibrillation: What Have We Learnt from CMR? [J].Diagnostics (Basel),2020;10(3):137.
[27] Jeong joo Woo, Dana C Peters, John V Wylie, et al.Correlation of Left Atrial Voltage Maps with Cardiovascular MR Provides Evidence of Preexistent Scar in Atrial Fibrillation Patients[J].Circulation, 2008,118:771-776.
[28] Canciello G, de Simone G, Izzo R, Giamundo A, Pacelli F, Mancusi C, Galderisi M, Trimarco B, Losi MA. Validation of Left Atrial Volume Estimation by Left Atrial Diameter from the Parasternal Long-Axis View[J]. J Am Soc Echocardiogr,2017;30(3):262-269.
[29] Bossard M, Knecht S, Aeschbacher S, Buechel RR, Hochgruber T, Zimmermann AJ, Kessel-Schaefer A, Stephan FP, Völlmin G, Pradella M, Sticherling C, Osswald S, Kaufma-nn BA, Conen D, Kühne M. Conventional versus 3-D Echocardiography to Predict Arrhythmia Recurrence After Atrial Fibrillation Ablation[J]. J Cardiovasc Electrophysiol,2017;28(6):651-658.
[30] Liao YC, Liao JN, Lo LW, Lin YJ, Chang SL, et al. Left Atrial Size and Left Ventricular End-Systolic Dimension Predict the Progression of Paroxysmal Atrial Fibrillation After Catheter Ablation[J]. J Cardiovasc Electrophysiol,2017;28(1):23-30.
[31] Njoku A, Kannabhiran M, Arora R, Reddy P, Gopinathannair R, Lakkireddy D, Dom-inic P. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a meta-analysis[J]. Europace,2018;20(1):33-42.
[32] Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Mohanty S, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation[J]. Circulation,2010;122(2):109-118.
[33] Kim MN, Lee JJ, Kim SA, Kim YH, Choi JI, Park SM, Park SW, Kim YH, Shim WJ. The difference of predictors for recurrence after catheter ablation of non-paroxysmal atrial fibrillation according to follow-up period[J]. Int Heart J,2014;55(4):312-318.
[34] Shiozawa T, Shimada K, Sekita G, Hayashi H, Tabuchi H, Miura S, Fujimoto S, Ka-doguchi T, Ouchi S, Aikawa T, Al Shahi H, Takahashi S, Miyazaki T, Sumiyoshi M, Na-kazato Y, Daida H. Left Atrial Appendage Volume and Plasma Docosahexaenoic Acid Le-vels Are Associated With Atrial Fibrillation Recurrence After Catheter Ablation[J]. Cardiol Res,2017;8(3):96-104.
[35] Pinto Teixeira P, Martins Oliveira M, Ramos R, Rio P, Silva Cunha P, Delgado AS, Pimenta R, Cruz Ferreira R. Left atrial appendage volume as a new predictor of atrial fibrillation recurrence after catheter ablation[J]. J Interv Card Electrophysiol,2017;49(2):165-171.
[36] Tian X, Zhang XJ, Yuan YF, Li CY, Zhou LX, Gao BL. Morphological and functionnal parameters of left atrial appendage play a greater role in atrial fibrillation relapse aft-er radiofrequency ablation[J]. Sci Rep,2020;10(1):8072.
[37] He Y, Zhang B, Zhu F, Hu Z, Zhong J, Zhu W. Transesophageal echocardiography measures left atrial appendage volume and function and predicts recurrence of paroxysmal atrial fibrillation after radiofrequency catheter ablation[J]. Echocardiography,2018;35(7):985-990.
[38] Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S.Atrial extracellular matrix remodelling in patients with atrial fibrillation[J]. J Cell Mol Med,2008;12:189‑208.
[39] Rog-Zielinska EA, Norris RA, Kohl P, Markwald R.The living scar‑cardiac fibroblasts and the injured heart[J]. Trends Mol Med, 2016;22: 99‑114.
[40] Kohl P and Gourdie RG.Fibroblast‑myocyte electrotonic coupling: Does it occur in native cardiac tissue?[J]. J Mol Cell Cardiol, 2014;70: 37‑46.
[41] Ongstad E and Kohl P.Fibroblast‑myocyte coupling in the heart:Potential relevance for therapeutic interventions[J]. J Mol Cell Cardiol, 2016;91: 238‑246.
[42] Nguyen TP, Qu Z and Weiss JN.Cardiac fibrosis and arrhythmogenesis: The road to repair is paved with perils[J]. J Mol Cell Cardiol, 2014;70: 83‑91.
[43] Krul SP, Berger WR, Smit NW, van Amersfoorth SC, Driessen AH, van Boven WJ, Fiolet JW, van Ginneken AC, van der Wal AC, de Bakker JM, Coronel R, de Groot JR. Atrial fibrosis and conduction slowing in the left atrial appendage of patients undergoing thoracoscopic surgical pulmonary vein isolation for atrial fibrillation[J].Circ Arrhythm Electrophysiol, 2015;8: 288‑295.
[44] Nattel S. Electrical coupling between cardiomyocytes and fibroblasts: Experimental testing of a challenging and important concept[J]. Cardiovasc Res, 2018;114: 349‑352.
[45] Pellman J and Sheikh F.Atrial fibrillation: Mechanisms, therapeutics, and future directi-ons[J]. Compr Physiol,2015;5:649‑665.
[46] Siebermair J,Kholmovski EG,Marrouche N.Assessment of left atrial fibrosis by late gadolinium enhancement magnetic resonance imaging[J].JACC Clin Electrophysiol,2017; 3: 791-802.
[47] Zghaib T, Keramati A, Chrispin J, Huang D, Balouch MA, Ciuffo L, Berger RD, M-arine JE, Ashikaga H, Calkins H, Nazarian S, Spragg DD.Multimodal examination of atrial fibrillation substrate[J].JACC Clin Electrophysiol,2018; 4: 59-68.
[48] Floria M, Radu S, Gosav EM, Cozma D, Mitu O, Ouatu A, Tanase DM, Scripcariu V, Serban LI. Left Atrial Structural Remodelling in Non-Valvular Atrial Fibrillation: What Have We Learnt from CMR? [J].Diagnostics (Basel),2020;10(3):137.
[49] Chen J, Arentz T, Cochet H, Müller-Edenborn B, Kim S, Moreno-Weidmann Z, Min-ners J, Kohl P, Lehrmann H, Allgeier J, Trenk D, Hocini M, Jais P, Haissaguerre M, Jad-idi A. Extent and spatial distribution of left atrial arrhythmogenic sites, late gadolinium enhancement at magnetic resonance imaging, and low-voltage areas in patients with persistent atrial fibrillation: comparison of imaging vs. electrical parameters of fibrosis and arrhythmogenesis[J]. Europace,2019;21(10):1484-1493.
[50] Qureshi NA, Kim SJ, Cantwell CD, Afonso VX, Bai W, et al. Voltage during atrial fibrillation is superior to voltage during sinus rhythm in localizing areas of delayed enhancement on magnetic resonance imaging: an assessment of the posterior left atrium in patients with persistent atrial fibrillation[J]. Heart Rhythm,2019;16:1357–1367.
[51] Jeong joo Woo, Dana C Peters, John V Wylie, et al.Correlation of Left Atrial Voltage Maps with Cardiovascular MR Provides Evidence of Preexistent Scar in Atrial Fibrillation Patients[J].Circulation, 2008,118:771-776.
[52] Ling LH, McLellan AJ, Taylor AJ, Iles LM, Ellims AH, Kumar S, Teh A, Lee G, Wong MC, Azzopardi S, Sellenger MA, Morton JB, Kalman JM, Kistler PM. Magnetic resonance postcontrast T1 mapping in the human atrium: validation and impact on clinical outcome after catheter ablation for atrial fibrillation[J]. Heart Rhythm,2014;11(9):1551-1559.
[53] Lee J, Thornhill RE, Nery P, Robert deKemp, Peña E, Birnie D, Adler A, Ukwatta E. Left atrial imaging and registration of fibrosis with conduction voltages using LGE-MRI and electroanatomical mapping[J]. Computers in Biology and Medicine, 2019, 111:103341.
[54] Yagishita A, Sparano D, Cakulev I, Gimbel JR, Phelan T, Mustafa H, De Oliveira S, Mackall J, Arruda M. Identification and electrophysiological characterization of early left atrial structural remodeling as a predictor for atrial fibrillation recurrence after pulmonary vein isolation[J]. J Cardiovasc Electrophysiol,2017;28(6):642-650.
[55] Begg GA, Karim R, Oesterlein T, Graham LN, Hogarth AJ, Page SP, Pepper CB, Rhode K, Lip GYH, Holden AV, Plein S, Tayebjee MH. Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation[J]. PLoS One,2018;13(1):e0189936.
[56] Masuda M, Fujita M, Iida O, Okamoto S, Ishihara T, Nanto K, Kanda T, Tsujimura T, Matsuda Y, Okuno S, Ohashi T, Tsuji A, Mano T. Left atrial low-voltage areas predict atrial fibrillation recurrence after catheter ablation in patients with paroxysmal atrial fibrillation[J]. Int J Cardiol,2018;257:97-101.
[57] Masuda M, Asai M, Iida O, Okamoto S, Ishihara T, Nanto K, Kanda T, Tsujimura T, Matsuda Y, Okuno S, Hata Y, Mano T. Additional Low-Voltage-Area Ablation in Patients With Paroxysmal Atrial Fibrillation: Results of the Randomized Controlled VOLCANO T-rial[J]. J Am Heart Assoc,2020;9(13):e015927.
[58] Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology[J]. Cold Spring Harb Perspect Biol. 2016;8(5):a021873.
[59] Wang Y, Cai H, Li H, Gao Z, Song K. Atrial overexpression of microRNA-27b atenuates angiotensin II-induced atrial fibrosis and fibrillation by targeting ALK5[J]. Hum Cell. 2018;31(3):251-260.
[60] Guo J, Jia F, Jiang Y, Li Q, Yang Y, Xiao M, Xiao H. Potential role of MG53 in the regulation of transforming-growth-factor-β1-induced atrial fibrosis and vulnerability to atrial fibrillation[J]. Exp Cell Res. 2018;362(2):436-443.
[61] Shen H, Wang J, Min J, Xi W, Gao Y, Yin L, Yu Y, Liu K, Xiao J, Zhang YF, Wang ZN. Activation of TGF-β1/α-SMA/Col I Profibrotic Pathway in Fibroblasts by Galectin-3 Contributes to Atrial Fibrosis in Experimental Models and Patients[J]. Cell Physiol Biochem. 2018;47(2):851-863.
[62] Cao F, Li Z, Ding WM, Yan L, Zhao QY. LncRNA PVT1 regulates atrial fibrosis via miR-128-3p-SP1-TGF-β1-Smad axis in atrial fibrillation[J]. Molecular Medicine, 2019, 25(1):7.
[63] Mumby S, Gambaryan N, Meng C, Perros F, Humbert M,Wort SJ,Adcock IM.Bromo-domain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension[J].Respirology,2017;22:157-164.
[64] Mio C, Conzatti K, Baldan F, Allegri L, Sponziello M,Rosignolo F, Russo D, Filetti S,Damante G.BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells[J].Oncol Rep,2018;39:582-588.